NSABP Members' Area
Password Protected - Access
Limited to NSABP Participating
NSABP Foundation, Inc.
General NSABP Information
Financial Conflicts of
IOM Report Group Comment
Contact the NSABP
Media Info on STAR
Clinical Trials Information
Clinical Trials Overview
Never Say Lost
Treatment Trials Information
Prevention Trials Information
Protocol P-1 - BCPT
Protocol P-2 - STAR
Related Web Sites
Medical Search Engines
To report problems, ask
questions or make comments,
please send e-mail to:
Systemic Therapy in Patients with Node-Negative Breast Cancer: A Commentary Based on Two National Surgical Adjuvant Breast and Bowel Project (NSABP) Clinical Trials
Fisher B, Redmond C, Wickerham DL, Wolmark N, Bowman D, Couture J, Dimitrov NV, Margolese R, Legault-Poisson S, and Robidoux A
Annals of Internal Medicine 111:703-712, 1989
Objective: To determine whether in the previous National Surgical Adjuvant Breast and Bowel Project (NSABP) studies of node-negative breast cancer there were either cohorts of patients with a prognosis favorable enough to preclude using systemic therapy or subsets of patients who failed to benefit from the treatments.
Design: Randomized clinical trials with stratification after surgery.
Setting: NSABP trials at institutions in the United States and Canada.
Patients: Data were collected on 731 eligible patients (Protocol B-13) with estrogen-receptor-negative tumors who randomly received either no therapy after surgery or sequential methotrexate and fluorouracil (M→F) followed by leucovorin. Data were also collected on 2834 patients (Protocol B-14) with estrogen-receptor-positive tumors who randomly received either placebo or tamoxifen treatment. The percentage of patients surviving disease-free was determined through 4 years of follow-up using life-table estimates.
Interventions: Protocol B-13 patients received 12 courses of M→F given intravenously on days 1 and 8 every 4 weeks. Leucovorin therapy was begun 24 hours after M→F administration. Protocol B-14 patients received 5-year treatment with either tamoxifen (10 mg twice daily by mouth) or placebo.
Results: When the outcome of untreated patients in either trial was related to the stratification variables, women were found to have a disease-free survival of less than 80% through 4 years of follow-up. This percentage is apt to decrease because the probability of treatment failure increases with time. In both trials, all subsets of women benefited from M→F or tamoxifen therapy.
Conclusion: The disease-free survival of all cohorts of node-negative patients with estrogen-receptor-negative or estrogen-receptor-positive tumors was poor enough to justify systemic treatment. The benefits of the therapies used are insufficient to eliminate the need for assessing putatively better regimens.
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA.